Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Conference Presentation (March 2024)
18 slides from Jagsonpal Pharmaceuticals's conference presentation, March 2024
Slide 1: Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Ltd.
Slide 2: Insight into Jagsonpal
Insight into Jagsonpal
Slide 3: Company Snapshot
Company Snapshot Legacy of 6 decades • Established in 1964, long track record of 59 years Focus Segments • Specialize in development & commercialisation of Gynaecology & Orthopaedic focussed products Leading Player • Among Top-10 companies operating in the Gynaecology segment Extensive Coverage • Co
Slide 4: Sales Team Overview
Pan India Presence Field force of 750+ with specialized product experience Sales Team Overview Super Stockist Products Strong available in network of C&FA 1,25,000+ 17 pan-India Depot pharmacies stocking across India points Warehouse 4
Slide 5: Why Jagsonpal
Why Jagsonpal Company with long heritage and brand equity with doctors Portfolio of strong brands in niche, smaller molecules – Top 10 brands account for 60% of revenue Sub-chronic portfolio, with intensive doctor engagement – less prone to genericization No NLEM exposure, nature of products also ma
Slide 6: Strong position in focus markets
Strong position in focus markets All values in ₹ Cr MAT MAT MAT VAL MS% MS% RANK RANK Companies JAN'22 JAN'23 JAN'24 GR% MAT JAN'23 MAT JAN'24 MAT JAN'23 MAT JAN'24 MANKIND 446.73 543.35 582.41 7% 10.23% 10.11% 2 1 ABBOTT 507.41 552.09 580.88 5% 10.39% 10.09% 1 2 SUN 328.52 359.13 376.38 5% 6.76% 6.
Slide 7: Strengths in Gynaecology therapeutic areas
Strengths in Gynaecology therapeutic areas Regular connect with 25,000 out of Contribute to 60% revenues of the 32,000 Gynecologist across the company country Present in all the Gynaecology Leaders in Progesterone sub-segments for last 5 decades therapeutic segment 2 out of 3 business divisions cate
Slide 8: Strengths in Orthopaedic therapeutic areas
Strengths in Orthopaedic therapeutic areas Regular connect with 12,000 out of 16,000 practicing Orthopedics along with 60,000 CP/ GPs in the country Presence in Osteoporosis segment for last 4 decades Dominate the pain-management Indomethacin market 8
Slide 9: Many Firsts to its credit in the country
Many Firsts to its credit in the country Concept of Pilfer- Sustained-Release Delayed-Release Proof Sterile Indomethacin Doxycycline Unipack (Metadec (Indocap SR) (Doxypal DR) inj, Maintane inj) A comprehensive Lycopene formulation (LycoRed) (Colla-2) for Osteoarthritis 9
Slide 10: Leadership position: Demonstrated ability to build leading brands
Leadership position: Demonstrated ability to build leading brands Ranked #1 Antioxidants – LycoRed NSAIDs – Indocap SR Allylestrenol – Maintane Tablet Ranked #2 17a-HPC – Maintane Injection Dienogest – EndoReg Anabolic Steroids – Metadec Anti-spasmodics – Equirex 10
Slide 11: Progress & Way Forward
Progress & Way Forward
Slide 12: Journey in last 18 months
Journey in last 18 months Leveraged strategic development of Dydrogesterone to create strong franchise – Divatrone was awarded 1st runner in “New Introductions by Companies up to 500 Cr” by AWACS Marketing Awards 2022 Streamlined operations with improved quality of business and lower costs, operatin
Slide 13: YTD FY23 Update
YTD FY23 Update Overall Growth compromised with challenges in top 2 brand franchise of the company Dydrogestrone – Had emerged as the largest franchise of the company within 18 months of launch, hyper-competition led to strategic course correction with significant reduction in sales – ProRetro disco
Slide 14: Way Forward – FY25
Way Forward – FY25 Significant new launches planned across divisions – Platform established for faster growth Focus on strengthening presence with core set of prescribers - Gynae and Orthopedics, CPs/ GPs Explore in-licensing opportunities by leveraging internal strong sales & distribution capabilit
Slide 15: Financial Performance
Financial Performance
Slide 16: Profit and Loss Statement
Profit and Loss Statement All values in ₹ Mn Particulars YTD Dec 23 YTD Dec 22 FY 23 FY 22 Revenue From Operations 1,652 1,813 2,367 2,176 Material Consumption -629 -706 -931 -890 Gross Margin 1,023 1,107 1,436 1,286 % 61.9% 61.1% 60.7% 59.1% Employee Benefit Expenses -371 -432 -564 -577 Operating E
Slide 17: Key Balance sheet Items
Key Balance sheet Items All values in ₹ Mn Particulars As at As at As at 31 Dec 23 31 Mar 23 31 Mar 22 Shareholders' Funds 1794 1,589 1,328 Tangible Assets 10 184 226 Assets Held for Sale 172 0 0 Financial Assets (Cash & Equivalents) 1,357 1,169 254 Investments 10 11 507 Other Non-Current Assets (Ne
Slide 18: Thank You
Thank You Registered Office: T-210 J, Shahpur Jat New Delhi - 110 049 Corporate Office: Nimai Tower, 3rd Floor, Plot No: 412-415, Phase – IV, Udyog Vihar, Gurugram, Haryana - 122015 Tel. : 0124-4406710 E-mail : info@jagsonpal.com Website : www.jagsonpal.com CIN: L74899DL1978PLC009181
Jagsonpal Pharmaceuticals — Conference Presentation (March 2024) on 6ix